OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Nguyen on the Optimal Duration of ADT in High-Risk Prostate Cancer

September 23rd 2020

Paul L. Nguyen, MD, discusses the optimal duration of androgen deprivation therapy in patients with high-risk prostate cancer.

Dr. Shore on the Objective of the HERO Trial in Advanced Prostate Cancer

September 23rd 2020

Neal D. Shore, MD, FACS, discusses the objective of the phase 3 HERO trial in advanced prostate cancer.

Dr. Choudhury on Treatment Goals in Nonmetastatic CRPC

September 23rd 2020

Atish D. Choudhury, MD, PhD, discusses the goal of treating patients with nonmetastatic castration-resistant prostate cancer.

Dr. Shoushtari on the Design of the CheckMate-067 Trial in Advanced Melanoma

September 22nd 2020

Alexander N. Shoushtari, MD, discusses the design of the phase 3 CheckMate-067 trial in advanced melanoma.

Dr. Zonder on the ZUMA-2 and ZUMA-5 Trials in MCL and iNHL

September 22nd 2020

Jeffrey Zonder, MD, discusses the ZUMA-2 trial in mantle cell lymphoma and the ZUMA-5 trial in indolent non-Hodgkin lymphoma.

Dr. Deol on the Nuances of Utilizing CAR T-Cell Therapy in Lymphoma and Leukemia

September 22nd 2020

Abhinav Deol, MD, discusses the nuances of utilizing CAR T-cell therapy in lymphoma and leukemia.

Dr. Pagel on the Utility of CAR T-Cell Therapy in Relapsed/Refractory DLBCL

September 22nd 2020

John M. Pagel, MD, PhD, discusses the utility of CAR T-cell therapy in patients with relapsed/refractory diffuse large B-cell lymphoma.

Dr. Welslau on the Rationale for the REFLECT Trial With Rituximab Biosimilar

September 22nd 2020

Manfred Welslau, MD, discusses the rationale of the prospective REFLECT trial with the rituximab biosimilar SDZ-RTX in patients with diffuse large B-cell lymphoma.

Dr. Seymour on the Kinase Selectivity of BTK Inhibitors in CLL

September 22nd 2020

Erlene Seymour, MD, discusses the kinase selectivity of BTK inhibitors in chronic lymphocytic leukemia.

Dr. Choudhury on the Safety Profiles of Antiandrogens in Nonmetastatic CRPC

September 22nd 2020

Atish D. Choudhury, MD, PhD, compares the safety profiles of antiandrogen agents in nonmetastatic castration-resistant prostate cancer.

Dr. Hussain on the Safety Profile of Olaparib in the PROfound Trial in mCRPC

September 22nd 2020

Maha Hussain, MD, FACP, FASCO, discusses the safety profile of olaparib as observed in the phase 3 PROfound trial in men with metastatic castration-resistant prostate cancer.

Dr. Trinh on Re-Establishing Standard Surgical Procedures in Prostate Cancer

September 22nd 2020

Quoc-Dien Trinh, MD, discusses the challenges of re-establishing standard surgical procedures in patients with prostate cancer following the initial wave of the coronavirus disease 2019 pandemic.

Dr. Nowakowski on the Rationale of the ENGINE Trial in DLBCL

September 22nd 2020

Grzegorz S. Nowakowski, MD, discusses the rationale for the ongoing, randomized phase 3 ENGINE study in diffuse large B-cell lymphoma.

Dr. Hill on the SADAL Trial With Selinexor in DLBCL

September 22nd 2020

Brian T. Hill, MD, PhD, discusses the data from the SADAL trial that led to the FDA approval of selinexor for use in patients with diffuse large B-cell lymphoma.

Dr. Maddocks on Remaining Challenges in Follicular Lymphoma

September 22nd 2020

Kami J. Maddocks, MD, discusses remaining challenges in treating patients with follicular lymphoma.

Dr. Trinh on the Impact of the COVID-19 Pandemic on Prostate Cancer

September 21st 2020

Quoc-Dien Trinh, MD, discusses the impact of the coronavirus disease 2019 pandemic on prostate cancer.

Dr. Choudhury on the Different States of Nonmetastatic CRPC

September 21st 2020

Atish D. Choudhury, MD, PhD, discusses the different states of nonmetastatic castration-resistant prostate cancer.

Dr. Nguyen on Future Research in High-Risk Prostate Cancer

September 21st 2020

Paul L. Nguyen, MD, discusses future research in high-risk prostate cancer.

Dr. Zalcberg on Updated Results from the Phase 3 INVICTUS Study in Advanced GIST

September 20th 2020

John Zalcberg, PhD, OAM, discusses updated results from the phase 3 INVICTUS trial in advanced gastrointestinal stromal tumor.

Dr. Skarbnik on the Importance of Personalized Treatment for Follicular Lymphoma

September 19th 2020

Alan P. Z. Skarbnik, MD, discusses the importance of personalizing treatment for patients with follicular lymphoma.